Determining the ER status of a tumor is essential for guiding treatment. This is typically done through immunohistochemistry (IHC), which uses antibodies to detect ER proteins in the cancer cells. The results are reported as a percentage of ER-positive cells and are used to decide if endocrine therapy is appropriate.
